Ribo Newsroom
-
Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNAInnovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.April 8, 2024 -
Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesBoehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseasesJanuary 3, 2024 -
Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9December 25, 2023 -
Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023Ribo is to Present the Latest Research Data on Two Investigational siRNA Drugs under Development at EASL2023April 20, 2023 -
Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in AustraliaSuzhou Ribo Life Science Co., Ltd. announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.February 9, 2023 -
Ribo Announces Successful Passing EU GMP Audit.Suzhou Ribo Life Science Co., Ltd. announced today that it has recently received the European Union Qualified Person Declaration (QPD) from the Qualified Person based on the positive results of the EU GMP audit conducted for its oligonucleotide manufacturing facilities located in Kunshan, China.October 26, 2022